title: Concurrent sunitinib and stereotactic body radiotherapy for patients with oligometastases: final report of a prospective clinical trial.
abstract: Preliminary results demonstrated that concurrent sunitinib and stereotactic body radiation therapy (SBRT) is an active regimen for metastases limited in number and extent. This analysis was conducted to determine the long-term survival and cancer control outcomes for this novel regimen. Forty-six patients with oligometastases, defined as five or fewer clinical detectable metastases from any primary site, were treated on a phase I/II trial from February 2007 to September 2010. The majority of patients were treated with 37.5 mg sunitinib (days 1-28) and SBRT 50 Gy (days 8-12 and 15-19) and maintenance sunitinib was used in 39 % of patients. Median follow up for surviving patients is 3.6 years. The 4-year estimates for local control, distant control, progression-free and overall survival were 75 %, 40 %, 34 % and 29 %, respectively. At last follow-up, 26 % of patients were alive without evidence of disease, 7 % were alive with distant metastases, 48 % died from distant metastases, 2 % died from local progression, 13 % died from comorbid illness, and 4 % died from treatment-related toxicities. Patients with kidney and prostate primary tumors were associated with a significantly improved overall survival (hazard ratio = 0.25, p = 0.04). Concurrent sunitinib and SBRT is a promising approach for the treatment of oligometastases and further study of this novel combination is warranted.
authors: Department of Radiation Oncology, Good Samaritan Hospital Medical Center, 1000 Montauk Highway, West Islip, NY, 11795, USA, johnny.kao@chsli.org.
authors: Johnny
authors: J
authors: Kao
authors: Chien-Ting
authors: CT
authors: Chen
authors: Charles C L
authors: CC
authors: Tong
authors: Stuart H
authors: SH
authors: Packer
authors: Myron
authors: M
authors: Schwartz
authors: Shu-Hsia
authors: SH
authors: Chen
authors: Max W
authors: MW
authors: Sung
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D059248:Chemoradiotherapy; D003131:Combined Modality Therapy / Q000379:methods*; D005260:Female; D006801:Humans; D007211:Indoles / Q000008:administration & dosage*; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis / Q000628:therapy*; D011758:Pyrroles / Q000008:administration & dosage*; D016634:Radiosurgery / Q000379:methods*; D000077210:Sunitinib
chemical_list: D000970:Antineoplastic Agents; D007211:Indoles; D011758:Pyrroles; D000077210:Sunitinib
references: N Engl J Med. 1990 Feb 22;322(8):494-500
references: 2405271
references: Lancet. 2004 May 22;363(9422):1665-72
references: 15158627
references: Nature. 1998 Jul 16;394(6690):287-91
references: 9685160
references: Cancer Res. 2003 Jul 15;63(14):4009-16
references: 12873999
references: Clin Cancer Res. 2009 Mar 15;15(6):2148-57
references: 19276286
references: N Engl J Med. 2012 Mar 8;366(10):925-31
references: 22397654
references: Cancer. 2008 Feb 1;112(3):650-8
references: 18072260
references: Cancer Res. 2009 Mar 15;69(6):2514-22
references: 19276342
references: Nat Clin Pract Oncol. 2007 Feb;4(2):86-100
references: 17259930
references: J Clin Oncol. 2007 Mar 1;25(7):884-96
references: 17327610
references: J Clin Oncol. 2009 Apr 1;27(10):1585-91
references: 19255313
references: Cancer. 2012 Jun 1;118(11):2962-70
references: 22020702
references: J Clin Oncol. 1995 Jan;13(1):8-10
references: 7799047
references: JAMA. 2011 Feb 2;305(5):487-94
references: 21285426
references: J Nucl Med. 2009 May;50 Suppl 1:122S-50S
references: 19403881
references: J Clin Oncol. 2009 Apr 1;27(10):1572-8
references: 19255321
references: Int J Radiat Oncol Biol Phys. 2001 Nov 1;51(3):666-70
references: 11597807
references: Nat Rev Clin Oncol. 2011 Jun;8(6):378-82
references: 21423255
references: Clin Cancer Res. 2008 Aug 15;14(16):5255-9
references: 18698045
references: Nat Biotechnol. 2008 Jan;26(1):127-32
references: 18183025
references: N Engl J Med. 2007 Jan 11;356(2):115-24
references: 17215529
references: Cancer. 2009 Aug 1;115(15):3571-80
references: 19536893
references: CA Cancer J Clin. 2009 May-Jun;59(3):145-70
references: 19364702
references: PLoS One. 2012;7(6):e36979
references: 22761653
references: J Clin Oncol. 2007 Mar 10;25(8):947-52
references: 17350943
references: Int J Radiat Oncol Biol Phys. 2012 Jul 1;83(3):878-86
references: 22172903
references: Neurosurgery. 2004 Jul;55(1):89-98; discussion 98-9
references: 15214977
references: Crit Rev Oncol Hematol. 2011 Jan;77(1):12-9
references: 20304669
references: Radiat Oncol. 2008 Oct 31;3:36
references: 18976463
references: Int J Oncol. 2004 Dec;25(6):1677-83
references: 15547705
references: J Clin Oncol. 2009 Apr 1;27(10):1579-84
references: 19255320
references: Acta Oncol. 2009;48(4):578-83
references: 19373699